Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares Semiconductor ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.78B), while iShares Semiconductor ETF trades at $544.69. The key difference: iShares Semiconductor ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SOXX | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $655.01 |
52-Week Low | $2.84 | $241.68 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.
The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.
SOXX trades at $546.61, up 3.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Support lies near $530 and resistance at $548. Recent news highlights sector volatility, including a 21% drop in July 2026 due to headwinds like short-seller commentary and competitive pressures, though cloud company growth supports AI spending optimism.
The outlook is mixed: strong AI demand from cloud providers offers upside, but concentration risk and tariff uncertainties pose threats. Investors face volatility from sector rotations and geopolitical factors, requiring careful risk assessment amid evolving semiconductor dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
